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INTRODUCTION
The recent successes of integration-competent lentiviral vectors 
(ICLVs) targeting patients’ hematopoietic stem cells (HSC) in alter-
ing the pathologic course of fatal genetic diseases have opened a 
new avenue in treating incurable diseases.1–4 However, the prospect 
of broadening the usage of the above therapeutic methodology to 
include nonfatal diseases is limited by the risk of insertional muta-
genesis inherent to all integrating vectors. Indeed, data accumulated 
from various preclinical studies have raised major concerns regarding 
the oncogenic potential of gamma-retroviral and lentiviral vectors.5–10 
These concerns have materialized in several human clinical trials in 
which autologous bone marrow transplantation of gamma-retroviral 
vector-transduced HSC resulted in tumor development.11–13 Taking a 
similar therapeutic approach, Cavazzana-Calvo et  al.4 have success-
fully employed ICLV’s to deliver a β-globin gene expression cassette 
to patients’ HSC as a means to treat β-thalassemia. However, reports 
from this trial describe clonal expansion of the myeloid lineage due to 
vector-mediated insertional mutagenesis, leading to dysregulation of 
the HMGA2 gene in progenitor cells.
Biosafety concerns regarding ICLV-associated insertional muta-
genesis and the desire to harness the advantages of lentiviral vec-
tors—including low immunogenicity, high capacity, and the ability 
to transduce nondividing cells—were the impetus for the develop-
ment of integration-defective lentiviral vectors (IDLVs). Generally, 
IDLVs are packaged into vector particles carrying class I integrase 
mutants in which one amino acid in the DDE conserved catalytic 
triad (predominantly the D64 residue) is mutated.14–21 Several stud-
ies have  demonstrated different levels of illegitimate integrase-
independent integration (up to one integration event per 200 vector 
genomes).14,20,22–24 However, the development of the polypurine tract 
(PPT)-deleted IDLVs by Kantor et al. has significantly reduced the lev-
els of illegitimate integration.24,25
IDLVs have efficiently transduced a plethora of cell lines and 
various primary cells including human embryo fibroblasts, human 
macrophages, HSC, primary neuronal cells, and embryonic stem 
cells.14,16,18–20,22,24,26–33 Different laboratories have demonstrated the 
ability of IDLVs to maintain long-term expression of reporter genes 
in non-dividing cells in various target organs, including the CNS, spi-
nal cord, muscle, eye, and liver.14,16,18,20,27,31,34,35 Furthermore, Thrasher 
et al. and Suwanmanee et al. have successfully employed IDLVs in 
mouse models of gene replacement therapy for degenerative reti-
nal disease and hemophilia B.35,36 The efficacy of IDLVs in cancer 
immunotherapy and as a means of inducing protective immune 
responses to human pathogens has been characterized in different 
experimental settings.37–46 Importantly, a growing number of manu-
scripts have described IDLVs carrying either zinc-finger nucleases, 
and the CRISPR-Cas 9 system as an effective means of gene editing 
for clinical and basic science applications.47–52
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The risk of insertional mutagenesis inherent to all integrating exogenous expression cassettes was the impetus for the develop-
ment of various integration-defective lentiviral vector (IDLV) systems. These systems were successfully employed in a plethora 
of preclinical applications, underscoring their clinical potential. However, current production of IDLVs by transient plasmid 
transfection is not optimal for large-scale production of clinical grade vectors. Here, we describe the development of the first 
 tetracycline-inducible stable IDLV packaging cell line comprising the D64E integrase mutant and the VSV-G envelope protein. 
A conditional self-inactivating (cSIN) vector and a novel polypurine tract (PPT)-deleted vector were incorporated into the newly 
developed stable packaging cell line by transduction and stable transfection, respectively. High-titer (~107 infectious units (IU)/ml)  
cSIN vectors were routinely generated. Furthermore, screening of single-cell clones stably transfected with PPT-deleted vector 
DNA resulted in the identification of highly efficient producer cell lines generating IDLV titers higher than 108 IU/mL, which upon 
concentration increased to 1010 IU/ml. IDLVs generated by stable producer lines efficiently transduce CNS tissues of rodents. Overall, 
the availability of high-titer IDLV lentivirus packaging cell line described here will significantly facilitate IDLV-based basic science 
research, as well as preclinical and clinical applications.
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In the early stages of retroviral vector development, production 
of gamma-retroviral vectors was premised on stable packaging cell 
lines.53 The establishment of the highly transfectable 293T in the 
early 90’s allowed Pear et al.54 to produce high-titer retroviral vec-
tors by transient transfection. The ability to pseudotype retroviral 
vectors with the VSV-G envelope further facilitated production of 
high-titer retroviral vector particles.55 Premised on the aforemen-
tioned advancements in retroviral vector production, Naldini 
et  al.56 employed transient three-plasmid transfection to produce 
and concentrate VSV-G pseudotyped lentiviral vector to transduce 
murine neurons in vivo. Similar successes employing transient plas-
mid transfection in producing high-titer lentiviral vectors rendered 
this approach most popular. Notwithstanding the ease of produc-
ing high-titer lentiviral vectors by transient transfection, the need 
to scale up vector production, to reduce variability between vec-
tor preparations, and to reduce the risk of emerging replication 
competent retroviruses (RCRs) were the drive for the establishment 
of several stable ICLV packaging cell lines.57–62
Here, we describe the establishment of the first IDLV packaging 
cell line, which generates high titer, VSV-G pseudotyped conditional 
SIN and PPT-deleted IDLVs. The vectors efficiently transduce rodent 
CNS. The novel packaging cell line will facilitate the scaling up in 
production of safer IDLVs more suitable for clinical trials.
ReSUlTS
The establishment of the IDLV inducible stable packaging cell line
Maximizing vector biosafety and titers are the main guidelines to be 
followed in establishing all lentiviral viral vector stable packaging 
cell lines. Encouraged by earlier studies of  VSV-G pseudotyped lenti-
viral vectors demonstrating efficient transduction of brain and liver 
tissues in vivo and HSC ex vivo, we based the first IDLV packaging 
Figure 1  Schematic outline for generating tetracycline-regulated integration-defective lentiviral vector packaging system. The PVG3 cell line 
constitutively expresses the synthetic tetracycline-regulated trans activator tTA under the control of a cytomegalovirus promoter, as well as the VSV-G 
envelope protein and the green fluorescent protein (GFP) marker gene from a bidirectional tetracycline-regulated expression cassette (depicted by a 
bidirectional arrow). Packaging cell lines were generated by stably transfecting PVG3 cells with the tetracycline-regulated HIV-1 packaging construct 
pTK1574, followed by G418 selection. p24gag enzyme-linked immunosorbent assay was used to identify and screen for high levels of particle production 
in cell clones expressing minimal—yet detectable—levels of GFP (in the presence of doxycycline (Dox)). Producer cell lines were further established 
by either transduction or stable transfection.
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cell line on this highly effective and broadly used envelope protein. 
To minimize the likelihood of emerging RCRs, we split the process 
of incorporating the VSV-G envelope and the packaging expression 
cassettes into the genome of the future packaging cells to two inde-
pendent stable transfection procedures (Figure  1). To address the 
potential hurdle associated with constitutive expression of the cyto-
toxic HIV-1 protease and the VSV-G envelope proteins,63–65 the afore-
mentioned expression cassettes were placed under the control of 
tetracycline-inducible promoters. The IDLV packaging construct 
(pTK1574) was established by placing an HIV-1 packaging cassette 
expressing the HIV-1 Gag, Pol, Tat, Rev, and Vpu under the control 
of a tetracycline inducible promoter (Figure 2a). A D64E HIV-1 inte-
grase mutant encoded by the above Pol gene renders the vector 
particles generated by the novel inducible packaging cassette inte-
gration defective. The efficiency of the novel packaging system at 
generating IDLVs in a tetracycline regulated fashion was evaluated 
by transiently transfecting it along with a conventional HIV-1 vector 
expressing the green fluorescent protein (GFP) under the control 
of a cytomegalovirus (CMV) promoter16 (pTK945, Figure 2a) and a 
VSV-G envelope expression cassette (pMDG) into SODk0 cells, either 
in the presence or absence of doxycycline (dox). The SODk0 cell line 
constitutively expresses the synthetic tetracycline regulated trans-
activator tTA.60 Physical and infectious titers of vector particles in 
culture media at 72 hours post-transfection were determined by 
p24gag enzyme-linked immunosorbent assay (ELISA) and by scoring 
GFP expression following serial vector dilutions on 293T cells. In the 
absence of dox, the novel packaging cassette supports efficient pro-
duction of physical (p24gag 142.8 ng/ml) and infectious vector par-
ticles (1.42 ± 0.11 × 107 IU/ml). Per contra, addition of Dox to culture 
media effectively inhibited vector production.
Encouraged by these results, we sought to stably transfect the 
inducible IDLV packaging cassette into the human embryo kid-
ney (HEK) 293-based PVG3 cell line, which was established in an 
earlier study.58 The PVG3 cells constitutively express the synthetic 
tetracycline-regulated trans activator tTA66 under the control of a 
CMV promoter, as well as the VSV-G envelope protein and the GFP 
marker gene from a bi-directional tetracycline-regulated expression 
cassette (Figure 1). As shown in Figure 2b,c, VSV-G and GFP expres-
sion is tightly regulated in PVG3 cells. In the presence of Dox, PVG3 
cells demonstrate a barely detectable VSV-G, and GFP expression. 
However, Dox withdrawal and addition of sodium butyrate (SB), a 
broad-spectrum histone deacetylase inhibitor resulted in robust 
VSV-G and GFP expression (Figure 2b,c).
As a first step in establishing the stable IDLV producing cell line, 
PVG3 cells were transfected with the inducible IDLV expression 
cassette (pTK1574, Figures 1 and 2) and a total of 50 G418-resistant 
cell clones were isolated and screened for minimal, yet detectable 
GFP expression in the presence of 1 µg/ml Dox. A total of 15 GFP 
expressing cell clones were identified, and p24gag ELISA was used 
to determine their ability to produce high levels of vector particles 
Figure 2 Generating tetracycline highly regulated integration-defective lentiviral vector (IDLV) packaging cell lines. (a) Depiction of the tetracycline 
inducible packaging vector pTK1574 containing the gag, pol (encoding the integrase-mutant D64E), vpu, rev, and tat genes under the control of 
a  tetracycline-regulated promoter and the HIV-1 vector pTK945 carrying the GFP marker gene under the control of a cytomegalovirus promoter. 
(b) Tight regulation of the VSV-G envelope and the IDLV packaging cassettes in PVG3 cells and in the stable packaging cell lines 3–8 and 3–12. The 
aforementioned cell lines were cultured either in presence of 1 µg/ml Dox or in the absence of Dox and in the presence of 5 mmol/l sodium butyrate. 
Expression of HIV-1 Gag (p55 and p24), Pol (p66 and p51) and the VSV-G envelope proteins in the above cell lines in the presence and absence of Dox 
were determined by western blot analysis. (c) Regulation of GFP expression in PVG3 and the packaging cell lines 3–8 and 3–12. The aforementioned 
cell lines were cultured either in presence of 1 µg/ml Dox or in the absence of Dox and in the presence of 5 mmol/l sodium butyrate. Expression of GFP 
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upon Dox withdrawal and addition of SB. Interestingly, condi-
tioned media obtained from the above 15 cell clones at 48 hours 
postexposure to SB exhibited a wide range of p24gag concentra-
tions, varying from undetectable levels up to 1,307.1 ng/ml. Next, 
we characterized the kinetics of vector particle production upon 
Dox withdrawal and addition of SB in the four cell clones exhibit-
ing the highest p24gag levels (3–6, 3–8, 3–10, and 3–12). As shown 
in Table 1, only moderate levels of p24gag were detected in condi-
tioned media of the four cell clones at 6 days post-Dox withdrawal 
(up to 817 ng/ml). However, all cell clones demonstrated a signifi-
cant increase in vector particle production at 2 days post-SB addi-
tion, and maintained high concentrations of p24gag in conditioned 
media up to 4 days postaddition of SB. However, increased cell 
death and morphological changes were observed in the above 
cell clones at 4 days post-SB exposure, indicating that between 
2 to 3 days post-SB addition is the optimal time frame for vector 
particles production.
Aware of the possibility that a residual expression of the HIV-1 
GagPol gene products in the presence of Dox may result in nega-
tive selection of vector particle producing cell clones, we sought to 
characterize the above cell clones’ stability. To this end, we cultured 
the four cell clones in the presence of Dox and in the absence of 
G418 for 4 weeks, after which production of vector particles was 
induced by Dox withdrawal and addition of SB. As shown in Table 1, 
all four cell clones exhibited kinetics and levels of vector particle 
production comparable to the levels detected prior to four weeks 
of cell culturing and expansion. These data indicate that the above 
cell clones are potential precursors of IDLV stable producer cell lines.
Establishing the first IDLV producer cell lines via transduction with 
conditional SIN vectors
Stable incorporation of vector genomes into packaging cells’ chro-
matin constitutes the last step in the process of establishing stable 
vector producer cell lines. This step can be mediated either by trans-
ducing or by transfecting stable packaging cell lines, either with vec-
tor particles or with vector plasmid DNAs, respectively. Introducing 
the vector cassettes by transduction is highly efficient and time 
saving, and was employed successfully in the past to generate high 
titer lentiviral and simple retroviral vector producer cell lines.60,67,68 
Since self-inactivating (SIN) vectors cannot be mobilized from trans-
duced target cells, this approach cannot be employed as a means 
to generate conventional SIN vector producing cell lines. This limi-
tation was addressed by the development of the conditional-SIN 
(cSIN) vectors, in which a tetracycline-regulated promoter replaced 
the parental U3-enhancer/promoter sequences. Consequently, cSIN 
vectors are efficiently mobilized from tTA expressing packaging cell 
lines, yet retain their SIN features in all tTA-lacking target cells.62 We 
sought to employ this technology to establish the first IDLV stable 
producer cell lines and to further characterize the ability of the 
Table 1 Stable production of vector particles by packaging cell lines
Clone name
P24gag (ng/ml)
+Dox -Dox day6 +SB day1 +SB day2 +SB day3 +SB day4
3–6 Beforea N/Ac 335.78 415.40 991.79 1,286.36 1,550.02
Afterb N/A 358.01 1,009.93 1,518.69
3–8 Before N/A 817.59 552.53 1,061.29 1,493.37 1,470.97
After N/A 820.37 1,279.10 1,769.85
3–10 Before N/A 629.42 557.78 1,272.87 1,282.77 1,546.23
After N/A 635.27 1,688.21 2,079.15
3–12 Before N/A 461.47 910.57 1,369.99 1,361.68 1,436.45
After N/A 628.28 1,279.05 1,444.14
Vector particle production by four packaging cell lines before (a) and after (b) four passages in culture (in the absence of G418) was initiated by Dox withdrawal from 
culture media. Sodium butyrate (SB, 5mM) was added to culture media after 6 days of induction. After 72 hours in conditioned media, vector particle concentration 
was determined by p24gag ELISA. N/A (c) indicates p24gag measurement not higher than background.
Figure 3 Generating tetracycline-regulated integration-defective 
lentiviral vector producer cell lines by transduction. (a) Depiction of the 
cSIN vector pTK136. Note that the 3’U3 region is replaced by  tetracycline-
regulated element. (b) Vector production by the aforementioned  vector-
producing cell lines (3-6-136, 3-8-136, 3-10-136, 3-12-136) was initiated 
by Dox withdrawal from culture media. Sodium butyrate (5 mmol/l) was 
added to culture media after 6 days of induction. Conditioned media 
were collected at 2–4 days after addition of sodium butyrate. Viral titers 
(IU/ml) were determined by scoring GFP expression by fluorescence 
microscopy following serial dilution of conditioned media on 293T cells.
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above four packaging cell lines (exhibiting the highest p24gag pro-
duction) to generate high-titer IDLVs.
To this end, we transduced the four packaging cell lines with the 
cSIN vector pTK136 (ref. 62) (Figures 1 and 3), from which the GFP 
reporter gene is expressed under the control of a CMV promoter. 
Heterogeneous pools of vector-transduced cell lines were induced 
to generate vector particles by Dox withdrawal and addition of 5 
mmol/l SB. Samples of conditioned media were collected between 
days 2–4 post-SB addition and IDLV titers were determined by scor-
ing GFP positive cells following serial dilution of conditioned media 
on 293T cells. As shown in Figure 3b, between days 2 and 4 post-SB 
exposure, the four novel IDLV producer cell lines generated vec-
tor titers higher than 106 IU/ml. However, IDLV titers (4–5 × 106 IU/
ml) generated by cell lines 3-8-136 and 3-12-136 were significantly 
higher than the titers (1–1.5 × 106 IU/ml) obtained from clones 
 3-6-136 and 3-10-136. Altogether, these results support the notion 
that cSIN vectors can rapidly and efficiently establish high titer IDLV 
producing cell lines.
Establishing the first IDLV PPT-deleted producer cell lines by stable 
transfection
Although time and labor consuming, stable transfection of plas-
mid vector DNA into stable packaging cells has been successfully 
employed to establish stable producer cell lines generating high 
titer SIN vectors.57–59,61 The fact that the efficiency of stable transfec-
tions is independent of the vector’s ability to successfully complete 
its life cycle renders this methodology highly suitable for generating 
stable producer cell lines of vectors unable to efficiently complete 
reverse transcription and integration. These include PPT-deleted 
vectors, which were developed as a means to further enhance vec-
tor biosafety by minimizing illegitimate, integrase-independent 
integration of IDLVs.24 PPT-deleted vectors cannot efficiently com-
plete reverse-transcription and thus generate minimal levels of 
linear vector genomes. The majority of PPT-deleted vectors are in 
the form of 1-LTR circles. Consequently, both integrase-mediated 
integration of PPT-deleted ICLVs and illegitimate integration of PPT-
deleted IDLVs are severely impaired.24 To combine the advantages 
conferred by employing a stable vector producing cell line with the 
enhanced biosafety properties of PPT-deleted vectors, we chose 
to stably transfect a PPT-deleted vector into stable packaging cell 
lines. Since both packaging cell lines (3–8 and 3–12) exhibited long-
term Dox-dependent expression of GagPol and GFP/VSV-G, and 
produced high titer cSIN IDLVs (Figures 2 and 3; Table 1), we chose 
to base the establishment of the first stable PPT-deleted IDLV pro-
ducer cell lines on the 3–8 and 3–12 packaging cells. To this end, 
plasmid DNA comprising both the PPT-deleted vector pTK1179 
cassette (expressing the GFP marker gene under the control of a 
CMV promoter) and the Bleocin resistance gene encoding cassette 
(Figures 1 and 4a) was transfected into the stable packaging cell lines 
3–8 and 3–12.
Two heterogeneous 3–8 and 3–12 cell pools and 30 single 
cell clones were isolated following Bleocin selection. Vector par-
ticle production from the above Bleocin resistant cell clones 
was induced by withdrawal of Dox and addition of 5 mmol/l SB. 
Concentration of p24gag and vector titers in conditioned media 
samples collected at 72 hours post-SB treatment was determined 
by ELISA and by scoring GFP expression following serial dilu-
tions of conditioned media on 293T cells. As shown in Table  2, 
both 3–8 and 3–12 cell pools generated comparable levels of 
p24gag concentrations and high titers of the PPT-deleted IDLV 
particles (1.1 ± 0.4 × 107 to1.6 ± 0.5 × 107 IU/ml). As expected, the 
above isolated cell clones exhibited a wide range of vector titers, 
which varied between 1.7 ± 0.5 × 106 IU/ml (clone 3-12-1179-11) to 
1.2 ± 0.3 × 108 IU/ml (clone 3-8-1179-1). Note that one cell clone 
(3-12-1179-14) failed to produce detectable levels of IDLVs (3-12-
1179-14). The concentrations of p24gag in the above conditioned 
media samples varied between 621 ± 146 ng/ml (clone 3-12-
1179-8) and 3,914 ± 1,275 ng/ml (clone 3-8-1179-2). Although cell 
lines producing low vector titers (<107 IU/ml) generated p24gag 
Table 2 Characterization of selected vTK1179 producer cell 
lines
Clone No. IUa/ml P24gag (ng/ml)b VCNc
3-8-1179 pool 1.1 ± 0.4 × 107 1,824 ± 445 13.9
3-12-1179 pool 1.6 ± 0.5 × 107 1,285 ± 443 58.9
3-8-1179-1 1.2 ± 0.3 × 108 2,801 ± 1,025 4.4
3-8-1179-2 2.8 ± 1.1 × 107 3,914 ± 1,275 2.7
3-12-1179-1 2.5 ± 0.2 × 107 2,024 ± 807 5.0
3-12-1179-2 2.6 ± 0.5 × 107 1,897 ± 699 7.6
3-12-1179-3 1.5 ± 0.3 × 107 1,296 ± 362
3-12-1179-4 3.4 ± 1.1 × 107 1,255 ± 261
3-12-1179-5 2.5 ± 0.9 × 106 1,698 ± 482 12.4






3-12-1179-12 5.6 ± 1.9 × 106 1,980 ± 423 28.5
3-12-1179-13 6.8 ± 0.6 × 106 1,581 ± 534




3-12-1179-19 5.2 ± 0.4 × 107 1,861 ± 270 10.2
3-12-1179-20 2.8 ± 0.9 × 107 1,174 ± 181
3-12-1179-21 3.1 ± 0.4 × 107 1,153 ± 126








Vector production was initiated by Dox withdrawal. Sodium butyrate (5 
mmol/l) was added to culture media after 6 days of induction. After 72 hours 
in conditioned media, vector titers (IU/ml, a) were determined by scoring 
GFP-positive cells following serial dilution on 293T cells. P24gag level (b) was 
determined by ELISA. Numbers represent mean ± SD (n = 3). VCNs (viral copy 
numbers, c) were measured by qPCR.
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concentrations lower than 2,000 ng/ml, there was no direct corre-
lation between p24gag concentrations and vector titers. To further 
characterize the above vector producing cells, vector copy num-
ber per diploid host genome (VCN) was determined by qPCR in 
the two cell pools and in 10 cell clones generating various vector 
titers. Interestingly, notwithstanding the fact that both cell pools 
produce comparable vector titers, the VCN in cell-pool 3-12-1179 
was more than fourfold higher than the VCN in cell-pool 3-8-1179. 
Similarly, VCN in the various cell clones was not correlated with 
vector titers generated by these vector producing cell lines. To 
characterize the above cell clones’ stability, we cultured the four 
producer cell lines (8–136, 12–136, 8-1179-1, and  8-1179-22) in 
the presence of Dox and in the absence of G418 for 5 weeks, after 
which production of vector particles was induced by Dox with-
drawal and addition of SB. As shown in Table 3, all four cell lines 
exhibited levels of vector particle and infectious unit production 
comparable to the levels detected prior to 5 weeks of cell cultur-
ing and expansion.
Efficient transduction of rodent CNS with stable producing cell 
line-generated IDLVs
The establishment of a stable IDLV producing cell line was aimed at 
facilitating large-scale IDLV production for in vivo applications. Thus, 
we sought to characterize the efficacy of IDLVs generated by the 
above stable vector producing cell lines at transducing rat CNS. To 
this end, IDLVs generated by cell clones 3-12-136, 3-12-1179-22 and 
3-8-1179-1 were concentrated and purified by ultracentrifugation 
as described by Kafri et al.60 Vector titers and concentration of p24gag 
were determined by scoring GFP expression following serial dilution 
on 293T cells and by p24gag ELISA, (3-12-1179-22: 2.70 × 1010 IU/ml, 
p24gag 1.24 × 106 ng/ml; 3-8-1179-1: 3.34 × 1010 IU/ml, p24gag 1.59 × 106 
ng/ml; 3-12-136, 1.28 × 109 IU/ml, p24gag 6.68 × 105 ng/ml, respec-
tively). Western blot analysis of concentrated vector particles using 
primary antibodies to HIV-1 p24gag and reverse-transcriptase proteins, 
as well as the VSV-G envelope proteins, demonstrated efficient vector 
particle formation and protein processing, which was comparable to 
ICLV and IDLV particles generated by transient transfection (Figure 4).
PPT-deleted IDLVs (pTK1179) generated by the novel stable 
 producer cell line 3-8-1179-1 and conventional ICLV’s (pTK945) 
generated by transient transfection were injected into the striatum 
of 300–350 g male sprague dawley rats (total of 0.66 × 107 IU and 
1.2 × 107 IU respectively). Transduction efficiency was determined at 
week 5 postinjection by confocal microscopy. As shown in Figure 5, in 
the rat striatum, ICLVs generated by transient transfection appeared 
to support moderately greater overall transduction in comparison 
to the cell line-generated PPT-deleted IDLVs (Figure  5a,b). These 
findings are in line with the higher number of injected ICLV IU 
and with an earlier study by Bayer et al.16 demonstrating reduced 
Table 3 Stability of vector producer cell lines
8–136 12–136 8-1179-1 12-1179-22
P24gag ng/ml Beforea — — 2801 ± 1025 2999 ± 109
Afterb 2374 ± 172 1047 ± 70 1716 ± 56 2952 ± 163
Titer IU/ml Before 4.0 ± 0.2 × 106 6.6 ± 1.2 × 106 1.2 ± 0.3 × 108 7.5 ± 0.2 × 107
After 5.7 ± 0.5 × 106 5.2 ± 0.4 × 106 1.1 ± 0.2 × 108 7.8 ± 0.3 × 107
Production of integration-defective lentiviral vector’s by four packaging cell lines before (a) and after (b) five passages in culture (in the absence of G418) was 
initiated by Dox withdrawal from culture media. Sodium butyrate (5 mmol/l) was added to culture media after 6 days of induction. After 72 hours in conditioned 
media, vector particle concentration was determined by p24gag ELISA. Vector titers (IU/ml) were determined by scoring GFP-positive cells following serial dilution 
on 293T cells. Numbers represent mean ± SD (n = 3).
Figure 4 Generating stable producer cell lines by transfection. (a) Depiction of the PPT-deleted vector pTK1179. SVori: SV40 promoter and origin; Bleo: 
Zeocin resistance gene; SVpA: SV40 polyadenylation signal; AmpR: Ampicillin resistance gene: (b) Western blot analysis of HIV-1 Gag (p55 and p24), Pol 
(p66 and p51) and the VSV-G envelope protein in vector particles generated by either transient transfection (pTK945 integration-competent lentiviral 
vectors and integration-defective lentiviral vector (IDLV)) and IDLV generated by the stable vector producer cell lines. Equal amounts of concentrated 
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transgene expression from episomal lentiviral vectors. Also, we 
observed that IDLV’s generated by a novel producer cell line effi-
ciently transduced murine striatum (data not shown). Interestingly, 
both ICLVs and IDLVs proved highly neurotrophic, such that almost 
all of the GFP-positive cells colocalized with the neuronal marker 
NeuN (Figure 5c,d). Furthermore, in the striatum virtually no GFP-
positive cells exhibited colocalization with glial fibrillary acidic pro-
tein, a cellular marker of astrocytes (Figure  5e). However, a major 
difference between the two vectors was observed in the corpus cal-
losum dorsal to the striatum. The nonintegrating vector exhibited 
little ability to transduce either oligodendrocytes or astrocytes in 
the corpus callosum, while the integrating vector efficiently trans-
duced both oligodendrocytes and astrocytes in the corpus callo-
sum dorsal to the striatum (Figure 5f ).
DISCUSSION
First stable IDLV packaging
IDLVs offer efficient gene delivery of large genetic cargos into 
dividing and nondividing cells with minimal risk of insertional 
mutagenesis (inherent in ICLVs). Increasingly, research groups 
have been employing these vectors as a means to deliver marker 
genes and therapeutic genetic cargos to a plethora of cell lines 
and primary cells in vitro and to various target organs in vivo. The 
successful  IDLV-based gene replacement therapy in mouse mod-
els of retinal degeneration35 and hemophilia B36 underscore their 
clinical potential. Furthermore, IDLVs have been used to transiently 
express genome-editing enzymes in dividing cells.49 Indeed, Yi 
et  al.52 have recently conferred resistance to HIV-1 infection by 
mutating the HIV-1 coreceptor CCR5 gene with IDLV-delivered 
zinc-finger-nucleases.
To further facilitate the use of IDLV’s, we report here on the 
establishment of the first stable IDLV cell lines. Titers of VSV-G-
pseudotyped IDLVs generated by the novel cell lines were higher 
than 108 and 1010 IU/ml prior to and after concentration, respec-
tively, and are comparable to or higher than titers of most currently 
used IDLVs and ICLVs generated by transient transfection.
Using the tetracycline inducible system, we circumvented the 
difficulties associated with overexpressing the cytotoxic HIV-1 
protease and the VSV-G envelope proteins. Importantly, the stable 
packaging cell lines generated in this study exhibited stability and 
maintained long-term, Dox-regulated expression of both the VSV-G 
envelope and HIV-1 GagPol gene products.
Our strategy for establishing the IDLV producer cell lines focused 
on minimizing the likelihood of emerging RCRs. Thus, all expression 
cassettes comprising the novel packaging system were introduced 
to the host genome separately using several independent rounds 
of stable transfection/selection procedures (Figure  1). Although 
time consuming, this approach minimizes the likelihood of 
 recombination-mediated RCR formation. Recent studies described 
the use of gamma-retroviral vectors as a means to incorporate 
the tetracycline-regulated trans-activator (tTA), envelope protein 
expression cassettes and the HIV-1 packaging system to 293T as 
a means to establish stable ICLV packaging cell lines.59,61 Although 
efficient, this approach raises biosafety concerns associated with 
mobilization of retroviral vectors carrying various components of 
the HIV-1 vector producing system, as well as increased likelihood of 
recombination-mediated RCR formation. These biosafety concerns 
were underscored by a recent publication demonstrating low yet 
detectable levels of lentiviral vector packaging of gamma-retroviral 
genomes.69 The tight transcriptional regulation of the VSV-G enve-
lope and the HIV-GagPol expression cassettes inhibits ongoing vec-
tor particle formation and consequently prevents superinfection of 
the stable packaging cell line with VSV-G-pseudotyped particles. 
This further reduces the likelihood of emerging RCRs.
In this study, we employed two different methodologies to intro-
duce the vector cassette into the packaging cell line. In one approach, 
we used cSIN vectors generated by transient transfection to trans-
duce the newly developed integrase-deficient packaging cell lines. 
This methodology is highly efficient and time saving. A pool of cSIN 
vector-transduced packaging cells generated IDLV titers higher than 
5 × 106 and 1 × 109 IU/ml prior to and after concentration. We predict 
that screening and isolating highly efficient single cell clones could 
further increase vector titers. The cSIN-based approach is optimal 
for rapid establishment of stable producer cell lines, yet it is prem-
ised on the ability of vectors generated by transient transfection 
Figure 5 In vivo striatal transduction by integrating and nonintegrating 
lentiviral vectors. Five weeks after bilateral 1 µl vector infusions, both the 
nonintegrating (panel a) and the integrating (panel b) lentiviral vectors 
transduced neurons in the rat striatum. The vast majority of transduced 
cells were neurons that colocalized with NeuN (panel c,  integration-
competent lentiviral vectors (ICLV); panel d, integration-defective 
lentiviral vector (IDLV); NeuN, red). Further example of this neuronal 
tropism is illustrated in panel e where confocal microscopy showed 
that glial fibrillary acidic protein (GFAP)-positive cells did not colocalize 
with GFP for the ICLV (GFAP, red). In contrast, the ICLV, but not the IDLV, 
transduced both oligodendrocytes and astrocytes (GFAP, red) in the 
corpus callsosum dorsal to the striatum (panel f, arrows indicate  GFP-
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to efficiently integrate into target cell genomes. Thus, it cannot be 
employed to transfer integration-impaired vectors such as att sites- 
or PPT- deleted vectors24,29 to packaging cell lines. Stable transfec-
tion of vector DNA to packaging cells is the second methodology 
described in this study for generating stable IDLV producing cell 
lines. We employed this methodology (which is independent of the 
vector’s integration efficiency) to incorporate PPT-deleted vectors 
into packaging cell lines. Transfection of linearized (nonconcatemer-
ized) vector plasmid DNA followed by Bleocin selection resulted in 
the establishment of two stable heterogeneous  vector-producing 
cell pools. These exhibited vector titers higher than 107 IU/ml with 
VCN’s of 14 and 59. As expected, 8 out of 30 isolated vector produc-
ing cell clones exhibited titers 2–10-fold higher (>108 IU/ml) than 
the titers generated by the above cell pools. The lack of correlation 
between p24gag concentration and VCN to vector titers suggests 
that identification of highly efficient vector producing cell clones 
cannot be based on these two parameters. The establishment of 
the first PPT-deleted IDLV producer cell lines enhances the overall 
biosafety of the IDLV system as it combines the advantage of mini-
mal illegitimate integration conferred by PPT-deleted vectors with 
the safety and efficiency gained by vector production by stable pro-
ducer cell lines.
Overall, the establishment of stable PPT-deleted and conven-
tional IDLV producing cell lines facilitates the usage and enhances 




The lentiviral vector pTK136, pTK1179, pTK945, and the packaging cassettes 
ΔNRF (Int+), pTK939 (Int-) were generated, as described previously.24,62 The 
inducible packaging system pTK1574 was derived by cloning a SacII/PvuI 
fragment containing the tetracycline-regulated element and the human 
CMV minimal promoter into similar sites in pTK939. The resultant pTK1574 
expresses the integrase-deficient (D64E) HIV packaging cassette (excluding 
the HIV-1 nef, vif, and vpr genes) under the control of a tetracycline regulated 
promoter.
Cells
The inducible IDLV packaging system is based on the PVG3 cell line,58 in which 
the synthetic trans-activator tTA is expressed under the control of a CMV pro-
moter. In addition, PVG3 cells express the VSV-G envelope and the GFP marker 
gene from a bidirectional tetracycline-inducible promoter. All cell types were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM)-High Glucose 
(Thermo Scientific, Waltham, MA) supplemented with 10% fetal bovine 
serum (FBS) (Atlantic Biologicals, Miami, FL), 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 250 ng/ml amphotericin B (Corning Cellgro, Manassas, VA). 
The PVG3 cell line and all its derivatives were cultured on poly-lysine 0.001% 
(Sigma, St Louis, MO) coated plates in the presence of 1 µg/ml Dox.
Viral vector production, concentration, and titration
Lentiviral vector production via three plasmids transient transfection was 
performed as previously described.56,62 The following plasmid amounts were 
used: 15 µg pTK945, 10 µg ΔNRF, and 5 µg of the VSV-G envelope plasmid 
pMD.G. Vector producing cells were regularly maintained in 1 µg/ml Dox. 
To induce vector production, cells were washed with phosphate-buffered 
saline (PBS) for three times, and passaged onto poly-lysine precoated plates 
in Dox-free medium. At 6 days post-Dox withdrawal, culture media were 
supplemented with 5 mmol/l SB. Viral vectors containing media were col-
lected at 60 hours after addition of SB.
For animal studies, viral vectors were concentrated by ultracentrifugation 
as previously described.60 The emergence of RCRs was ruled out by three 
independent safety assays (GFP rescue assay, Tat transfer assay, and Gag 
transfer assay), as previously described.60
Titers were determined by scoring GFP expression following serial 
dilutions on 293T cells. VCN was determined by multiplex PCR36 on the 
ABI7300 realtime PCR system. NotI794 primer/prober set (Left primer: 
 5′-taagaccaccgcacagca-3′; Right primer: 5′-cacttctccaattgtccctca-3′; Roche 
Universal Probe Library #25, 4686993001, Indianapolis, IN) was used for 
vectors detection, and paired with human GUSB primer/probe set (Roche 
5190525001, Indianapolis, IN) as the reference gene.
HIV-1 p24 ELISA
Titers of physical vector particles were determined by p24gag ELISA using the 
National Institutes of Health p24 Antigen Capture Assay kit, as previously 
documented.18
Western blot
Cells and vector particles were lysed in RIPA buffer and characterized for 
specific protein content by standard western blot analysis using denaturing 
10% SDS–PAGE gels. Blots were probed with a murine anti-VSV-G monoclo-
nal antibody (Ab) (1:1,000; P5D4, Santa Cruz, Dallas, TX), murine  anti-HIV-1 
RT (1:200, 5B2B2; NIH AIDS Research & Reference Reagent Program, 
Germantown, MD), and murine anti-HIV-1 p24 Gag (1:5,000, 6457; NIH AIDS 
Research & Reference Reagent Program) followed by a polyclonal goat anti-
murine secondary Ab labeled with horseradish peroxidase (1:10,000; Pierce, 
Grand Island, NY). Signals were detected by enhanced chemiluminescence 
(ECL) reagent (GE Health Amersham, Pittsburgh, PA).
Experimental animals
All of the animals were pathogen-free male Sprague–Dawley rats obtained 
from Charles Rivers. The animals were maintained in a 12-hour light–dark 
cycle and had free access to food and water. All care and procedures were in 
accordance with the Guide for the Care and Use of Laboratory Animals (DHHS 
Publication No. (NIH) 85-23), and all procedures received prior approval by the 
University of North Carolina Institutional Animal Care and Usage Committee.
For virus vector infusions, rats first were anesthetized with 50 mg/kg pento-
barbital and placed into a stereotaxic frame. Subsequently, each rat received 
a bilateral, striatal infusion (1 µl/side) of either the integrating (N = 3) or the 
nonintegrating (N = 3) lentiviral vector using a 32-gauge stainless steel injec-
tor and a Sage infusion pump (interaural line (IAL) 10.0 mm, lateral 3.0 mm, 
vertical 5.5 mm, according to the atlas of Paxinos and Watson, 1985). The 1 µl 
infusion occurred over a period of 5 minutes, and the injector was left in place 
for 3 minutes postinfusion to allow diffusion.
Immunohistochemistry
Five weeks after the vector infusions, the rats received an overdose of pen-
tobarbital (100 mg/kg pentobarbital, i.p.) and subsequently were perfused 
transcardially with ice-cold 0.1M sodium PBS (pH  =  7.4), followed by 4% 
paraformaldehyde in 0.1M phosphate buffer (pH = 7.4). After overnight fixa-
tion in the paraformaldehyde-phosphate buffer, vibratome sections (40 µm 
thick) were taken and rinsed in PBS. Tissue sections were incubated in 10% 
normal goat serum and 0.1% Triton X-100 in PBS for 30 minutes. Next, sec-
tions were incubated with a primary antibody to NeuN (1:1,000, Chemicon, 
Pittsburgh, PA)  or glial fibrillary acidic protein (1:4,000, DAKO A/S, Glostrup, 
Denmark) overnight in 3% normal goat serum, 0.2% Triton X-100 and PBS. 
Tissue sections were then rinsed in PBS, incubated in blocking serum (10% 
normal goat serum, 0.1% Triton X-100, PBS) for 1 hour and then incubated 
with a secondary fluorescent antibody (Alexa-fluor 594 goat anti-rabbit, or 
goat-anti-mouse, Molecular Probes) for 1 hour at 4 °C. Following three rinses 
in PBS, the sections were mounted on slides and coverslipped with fluo-
rescent mounting media. The eGFP and Alexa-fluor 594 fluorescence were 
visualized on either an Olympus IX 70 fluorescence microscope or a Leica 
SP2 laser scanning confocal microscope. All cases of colocalization were 
determined using the confocal microscope and the presence of colocaliza-
tion within a Z-stack.
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